The SURPASS clinical trial program showed mean heart rate increases of approximately 2 to 4 beats per minute
After a single intravenous (IV) administration, single intramuscular (IM) administrations at three doses in successive increments along with repeated IM administrations, the elimination half-life (t 1/2 ) of prototype BPC157 was less than 30 min, and BPC157 showed linear pharmacokinetic characteristics in rats and beagle dogs at all doses
Med Sci Sports Exerc 35(7):10931099
By boosting these normal reactions, GLP-1 medications help people manage their diabetes better and lose weight more effectively
GHRP-6 is not FDA-approved for any medical or therapeutic indication
Other policies (e.g., clinical policies) or contract terms may further determine whether a technology, procedure or treatment that is not addressed in the Payment Policy Manual is payable by Superior HealthPlan